AstraZeneca, GSK and more weathered Q2's economic headwinds, but Roche's stock took a hit: analysts

Blaming the “supply chain” has almost become a punch line—the go-to excuse for explaining any negative performance.

But these days it’s among a legitimate set of interrelated economic headwinds that include the Ukraine War, COVID lockdowns in China, inflation and the resulting rise in operational costs. Some companies—especially in Europe—are warning investors of these effects.